Literature DB >> 20855805

Supportive treatments for oncology patients: not just icing on the cake.

John F Deeken, Louis M Weiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20855805      PMCID： PMC3507510          DOI： 10.7326/0003-4819-153-6-201009210-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  11 in total

1.  Patient reports of complications of bone marrow transplantation.

Authors:  L A Bellm; J B Epstein; A Rose-Ped; P Martin; H J Fuchs
Journal:  Support Care Cancer       Date:  2000-01       Impact factor: 3.603

2.  Comparative effectiveness research: a report from the Institute of Medicine.

Authors:  Harold C Sox; Sheldon Greenfield
Journal:  Ann Intern Med       Date:  2009-06-30       Impact factor: 25.391

Review 3.  Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors.

Authors:  Paul W Finch; Jeffrey S Rubin
Journal:  J Natl Cancer Inst       Date:  2006-06-21       Impact factor: 13.506

4.  Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.

Authors:  Saroj Vadhan-Raj; Jonathan Trent; Shreyaskumar Patel; Xiao Zhou; Marcella M Johnson; Dejka Araujo; Joseph A Ludwig; Shana O'Roark; Ann M Gillenwater; Carlos Bueso-Ramos; Adel K El-Naggar; Robert S Benjamin
Journal:  Ann Intern Med       Date:  2010-09-21       Impact factor: 25.391

5.  Palifermin for oral mucositis after intensive therapy for hematologic cancers.

Authors:  Ricardo Spielberger; Patrick Stiff; William Bensinger; Teresa Gentile; Daniel Weisdorf; Tarun Kewalramani; Thomas Shea; Saul Yanovich; Keith Hansen; Stephen Noga; John McCarty; C Frederick LeMaistre; Eric C Sung; Bruce R Blazar; Dieter Elhardt; Mon-Gy Chen; Christos Emmanouilides
Journal:  N Engl J Med       Date:  2004-12-16       Impact factor: 91.245

6.  Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.

Authors:  Lee S Rosen; Ehtesham Abdi; Ian D Davis; John Gutheil; Frederick M Schnell; John Zalcberg; Alessandra Cesano; Urte Gayko; Mon-Gy Chen; Stephen Clarke
Journal:  J Clin Oncol       Date:  2006-10-30       Impact factor: 44.544

7.  Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.

Authors:  David M Brizel; Barbara A Murphy; David I Rosenthal; Kishan J Pandya; Stefan Glück; Herbert E Brizel; Ruby F Meredith; Dietmar Berger; Mon-Gy Chen; William Mendenhall
Journal:  J Clin Oncol       Date:  2008-05-20       Impact factor: 44.544

8.  American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

Authors:  Martee L Hensley; Karen L Hagerty; Tarun Kewalramani; Daniel M Green; Neal J Meropol; Todd H Wasserman; Gary I Cohen; Bahman Emami; William J Gradishar; R Brian Mitchell; J Tate Thigpen; Andy Trotti; Daniel von Hoff; Lynn M Schuchter
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

9.  Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.

Authors:  Linda S Elting; Ya-Chen Tina Shih; Patrick J Stiff; William Bensinger; Scott B Cantor; Catherine Cooksley; Ricardo Spielberger; Christos Emmanoulides
Journal:  Biol Blood Marrow Transplant       Date:  2007-04-23       Impact factor: 5.742

10.  Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT).

Authors:  John E Levine; Bruce R Blazar; Todd DeFor; James L M Ferrara; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.